Industry has only days to avert Turkish crisis
This article was originally published in Scrip
Executive Summary
The Turkish R&D pharmaceutical industry has only a few days left to avert the crisis being brought about by the government's new pricing decree, which aims to contain the cost of pharmaceuticals and could see the loss of 10-20% of the pharma workforce. Turkey is one of the key emerging pharmaceutical markets, worth some $11 billion in sales a year.